PharVision Advisers’s Ranger Energy Services RNGR Stock Holding History

PharVision Advisers’s Portfolio RNGR Stock Details RNGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,625	Closed	-$190K	–	534
2025 Q4	$190K	Buy	+13,625	New	+$185K	0.1%	580
2025 Q1	–	Sell	-15,849	Closed	-$245K	–	477
2024 Q4	$245K	Buy	+15,849	New	+$227K	0.21%	231

Other funds holding RNGR

IES Holdings Houston, Texas $214M AUM

ECA

Encompass Capital Advisors New York $3.34B AUM 167.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's RNGR Position: Q1 2026 in Review

PharVision Advisers sold out of Ranger Energy Services (RNGR) in Q1 2026, closing a stake of 13,625 shares — an estimated $190K sold.

PharVision Advisers first reported a position in RNGR in Q4 2024 and held it in 2 quarters. The position peaked at $245K in Q4 2024. 147 funds tracked by Wall St. Rank hold RNGR as of Q1 2026.

PharVision Advisers reported no remaining Ranger Energy Services position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 13,625 Ranger Energy Services shares in Q1 2026, an estimated $190K.
PharVision Advisers first reported a position in Ranger Energy Services in Q4 2024 and held it in 2 quarters.
PharVision Advisers's Ranger Energy Services position peaked at $245K in Q4 2024.
147 funds tracked by Wall St. Rank held Ranger Energy Services as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.